In additional cohorts of bladder cancer, patients with high RAD21 mRNA in the ERBB2-low cohorts showed tendency toward poor survival [Cohorts: Cohort four (GEO-GSE48075; with 5-year survival rates of 29.9% high vs. 53.7% low RAD21) and Cohort five the NMIBC (E-MTAB-4321; with 5-years survival rates of 83.3% high vs. 91.4% low RAD21)]; (Additional file 1: Fig. S2A,B, respectively). Here, ERBB2 is linked to urinary bladder cancer.